Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 9/20 | 0.33 |
| ▸ | JAK3 | P52333 | 3/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21678565 | 0.93 | JAK3 (0.40) | ADKPIK3CDPIK3R1JAK3PIK3CA | |
| SCHEMBL21678568 | 0.93 | JAK3 (0.40) | ADKPIK3CDPIK3R1JAK3PIK3CA | |
| SCHEMBL21678762 | 0.90 | JAK3 (0.40) | ADKJAK3 | |
| SCHEMBL21678758 | 0.90 | JAK3 (0.40) | ADKJAK3 | |
| SCHEMBL21678634 | 0.89 | ADORA1 (0.42) | ADKBTKPIK3CDPIK3CAADORA1 | |
| SCHEMBL21678453 | 0.85 | PIK3CD (0.39) | ADKPIK3CDPIK3R1JAK3PIK3CA | |
| SCHEMBL21678516 | 0.85 | JAK3 (0.38) | ADKBTKPIK3CDPIK3R1JAK3 | |
| SCHEMBL21701261 | 0.84 | ADORA1 (0.44) | BTKPIK3CDJAK3PIK3CAADORA1 | |
| SCHEMBL21701263 | 0.82 | ADORA1 (0.43) | BTKPIK3CDJAK3PIK3CAADORA1 | |
| SCHEMBL16765068 | 0.80 | JAK3 (0.41) | ADKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3833350-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | Aclaris Therapeutics, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20200048262-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2020-02-13 | — | — | US | disclosed |
| WO-2020033955-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048262-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ITK, PDXK, DMPK | ADK 163/4885BTK 558/4885PIK3CD 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.